Viatris announced its agreement to acquire Pacira BioSciences for $1.65 billion, significantly expanding its non-opioid pain management portfolio. This strategic acquisition is expected to be immediately accretive to Viatris' financial metrics and strengthens its position in a growing market, while Pacira shareholders receive a substantial premium.
Viatris is acquiring Pacira BioSciences for $1.65 billion, paying $36.50 per share in cash. This move is a significant strategic shift for Viatris, aiming to bolster its innovative medicines business, specifically in the non-opioid pain management sector, by adding established products like EXPAREL and ZILRETTA. For Pacira shareholders, this represents a substantial premium, leading to a significant surge in its stock price. Conversely, Viatris' stock saw a nearly 3% decline, likely due to the acquisition cost and potential integration challenges, despite management's expectation of immediate financial accretion and minimal impact on leverage. The deal is a major catalyst for both companies, reshaping Viatris' portfolio and offering a lucrative exit for Pacira investors, with short-term implications for VTRS's stock price and long-term potential for market share in non-opioid pain relief.